United Therapeutics Corporation $UTHR Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 88.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,960 shares of the biotechnology company’s stock after purchasing an additional 12,663 shares during the period. SG Americas Securities LLC owned approximately 0.06% of United Therapeutics worth $13,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics in the 2nd quarter worth $136,453,000. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its holdings in shares of United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after acquiring an additional 136,883 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.8%

Shares of UTHR opened at $522.83 on Friday. The firm has a market cap of $22.92 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $549.50. The company’s 50-day moving average price is $495.95 and its 200 day moving average price is $473.13.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the firm posted $6.19 earnings per share. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on UTHR shares. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research note on Monday, March 23rd. TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, HC Wainwright raised their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $549.91.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $479.51, for a total transaction of $10,788,975.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 356,320 shares of company stock worth $176,808,253. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.